Loading
Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma.
Joseph Connors was principal investigator of ECHELON-1, the trial showing brentuximab vedotin plus AVD improves progression-free and later overall survival compared with ABVD in advanced Hodgkin lymphoma, the first change to first-line therapy in decades. He built the BC Cancer lymphoid cancer database and population-based treatment guidelines that document real-world outcomes across all lymphomas.
Shares ECHELON-1, Brentuximab vedotin, Hodgkin lymphoma.
Shares Brentuximab vedotin, Antibody-drug conjugate (ADC) and the tag adc.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC) and the tag hodgkin.
Shares BC Cancer, Antibody-drug conjugate (ADC) and the tag canada.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC) and the tag hodgkin.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC).
Shares BC Cancer and the tag canada.
Shares ECHELON-1, ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma, Brentuximab vedotin, Hodgkin lymphoma.